Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.
You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!
If you have any problems with the registration process or your account login, please contact contact us.
Reuters are reporting: Cholesterol drugs act against diabetic nerve pain
Quote:
CHICAGO (Reuters) - New evidence suggests the same drugs that help reduce levels of artery-clogging cholesterol might prevent nerve damage brought on by diabetes, Australian researchers said on Friday.
They said an eight-year study of statins and fibrates -- two classes of cholesterol medication -- significantly cut the risk of developing peripheral sensory diabetic neuropathy, a condition that affects half of all diabetics.
The condition can cause stinging or burning sensations, tingling, pain, numbness or weakness in the hands and feet and is a major cause of amputations.
"The global impact of diabetic neuropathy is that there is an amputation about every 50 seconds," Dr. Aaron Vinik, director of the Streliz Diabetes Center at Eastern Virginia Medical School, said at the American Diabetes Association's scientific meeting in Chicago.
"It markedly affects people's quality of life," said Vinik, who moderated a press briefing.
Statins, the world's biggest-selling drugs, cut levels of LDL, or "bad" cholesterol, thus reducing the risk of heart attacks and stroke.
Fibrates are drugs that have been shown to raise levels of HDL, the so-called "good" cholesterol, and reduce triglyceride, a form of fat obtained through food.
Both drugs are already highly recommended for people with type 2 diabetes to help prevent heart attacks. Now they appear to help this type of nerve damage, said Dr. Timothy Davis, of the University of Western Australia, who led the study.
Davis and colleagues followed a group of about 400 diabetics over five years. All of the study participants had type 2 diabetes, which involves insulin resistance -- the body's inability to properly use its own insulin.
What they found is that statin drugs reduced the risk of developing peripheral neuropathy by 35 percent, and fibrates cut the risk by 48 percent. Because there was a wide and overlapping margin of error, the researchers said the effect was about the same for both types of drugs.
Patients in the study were taking Pfizer's atorvastatin, sold under the brand name Lipitor, or generic statins pravastatin and simvastatin. Fibrate drugs included gemfibrozil and fenofibrate.
"We believe these benefits are class effects of the drugs," Davis said.
Vinik said the results were important because there are currently no drugs approved in the United States to prevent the condition, only drugs to treat the pain it can cause.
Given that most diabetics already take statins to prevent heart complications, he said the problem of neuropathy will likely begin to improve for many diabetics as they continue on statin therapy.
This is somewhat paradoxical given that neuropathy is an uncommon side effect of some of the dyslipidaemic drugs
__________________
Craig Payne
Department of Podiatry
La Trobe University
Melbourne, Australia http://www.latrobe.edu.au/podiatry
__________________________________________________ ___________________________________ God put me on this earth to accomplish a certain number of things - right now I am so far behind, I will never die.
The views expressed above are those of the author and not that of La Trobe University This is where I am, where are you?
More on this from Medical News Today: Lipid-Lowering Drugs Protect Against Peripheral Diabetic Neuropathy
Quote:
A major epidemiological study conducted over eight years in Australia has shown that two classes of lipid- lowering drugs -- statins and fibrates -- significantly lower the risk of developing nerve damage known as peripheral sensory diabetic neuropathy, according to a report presented today at the American Diabetes Association's 67th Annual Scientific Sessions.
"Statins and fibrates, drugs already highly recommended for people with type 2 diabetes to help prevent heart attacks, now also appear to help prevent one form of diabetic nerve damage called 'peripheral neuropathy,' a common complication of diabetes," said Timothy Davis, MD, PhD, Professor of Medicine, at the University of Western Australia, and principal investigator of the study, in a recent interview. "Statins or fibrates reduced the risk of developing peripheral neuropathy by 35% or 48%, respectively, although these should be considered comparable risk reductions because of the wide confidence intervals." A correct estimate falls into a statistical range called a confidence interval, and the range in this instance means that the two estimates are indistinguishable, statistically speaking.
Peripheral neuropathy is the most common form of nerve damage caused by diabetes, affecting approximately 50% of those with diabetes. Damaged nerves can cause stinging or burning sensations, tingling, pain, numbness or weakness in the hands and feet. Although many medications have been used to treat the condition's symptoms, many fail, and preventing the condition by means other than controlling blood glucose levels, has also proven difficult. The project was essentially two studies in one: a large cross-sectional snapshot and a longitudinal five-year study of a subsection of the larger group.
Nearly 21 million Americans have diabetes, a group of serious diseases characterized by high blood glucose levels that result from defects in the body's ability to produce and/or use insulin. Diabetes can lead to severely debilitating or fatal complications, such as heart disease, blindness, kidney disease, nerve damage, and amputations. It is the fifth leading cause of death by disease in the U.S.
All of the study participants had type 2 diabetes, which involves insulin resistance -- the body's inability to properly use its own insulin. Type 2 used to occur mainly in adults who were overweight and ages 40 and older. Now, as more children and adolescents become overweight and inactive, type 2 diabetes is occurring more often in young people.
METHODOLOGY AND FINDINGS
The researchers assessed the relationship between lipid-lowering therapy and the prevalence and incidence of peripheral neuropathy, based on scoring on the Michigan Neuropathy Screening Instrument -- one of the most sensitive and specific tools for screening for the condition -- in a large representative cohort of adults. Prevalence measures how much of a disease or condition there is in a population at a particular point in time. Incidence measures the rate of occurrence of new cases of a disease or condition.
The cross-sectional sample was comprised of all 1,294 of those recruited to the Fremantle Diabetes Study between 1993 and 1996.
At their entrance into the study, the participants average age was 64 years, with their diabetes diagnosed four years previously, 48.8% were male, and 30.9% had neuropathy. Fibrates and statins were used by 3.5% and 6.8%, respectively.
Older age, longer diabetes duration, central adiposity, increasing height, higher fasting plasma glucose, higher systolic blood pressure, higher urinary albumin to creatinine ratios, and indigenous racial background were all independently associated with prevalent peripheral neuropathy at baseline, while use of fibrates was associated with a 70% reduction in neuropathy prevalence.
The longitudinal sub-group was comprised of 531 people who had attended six comprehensive annual health assessments by November 2001. Use of fibrates and statins increased to 10.4% and 36.5%, respectively, during the five years of follow-up. The results were controlled for potential confounding variables, including changes in A1C levels, a measure of long-term blood glucose control.
Time to development of newly diagnosed peripheral neuropathy in the longitudinal sub-group showed that fibrates and statins reduced neuropathy risk by 48% and 35% respectively. Further, they may have independent action. "In our analysis, the beneficial effects of the drugs were independent of each other and they may work through different mechanisms," said Dr. Davis. "It's just a hypothesis, but taking both drugs may yield greater benefit than taking either drug alone."
At the outset, in the cross-sectional study, the fibrate participants were using gemfibrozil, and the statins in use were atorvastatin, simvastatin and pravastatin. At the end of the longitudinal study, gemfibrozil continued to be the primary fibrate used, although some had begun to use fenofibrate. By then atorvastatin was the predominant statin, although simvastatin and pravastatin also continued to be in use.
"We believe these benefits are class effects of these drugs," said Dr. Davis. While many mechanisms have been proposed, their mechanism of action in neuropathy remains unknown. The leading theory for statins seems to be a reduction of both inflammation and oxidative stress.
RECOMMENDATIONS
Although laboratory and animal studies have provided evidence that both statins and fibrates may protect against nerve damage, anecdotal clinical reports have associated their use with a reversible clinical neuropathy. In light of the new findings, Dr. Davis suggested that such reports may have been coincidence -- the individuals were developing neuropathy anyway -- or perhaps that there may be a small number of people who were sensitive to the drug but, he emphasized, with greater numbers who may benefit from taking it.
"People with diabetes should not shy away from taking these drugs for both heart and neuropathy benefits," he said. "Whether a fibrate or statin should be taken is never an easy choice, but a statin is usually the first line drug because of the strong evidence of cardiovascular disease prevention benefits."
Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study
T. M. E. Davis, B. B. Yeap, W. A. Davis and D. G. Bruce Diabetologia Volume 51, Number 4 / April, 2008
Quote:
Aims/hypothesis The aim of this study was to assess the relationships between lipid-lowering therapy and the prevalence and incidence of peripheral sensory neuropathy in type 2 diabetes mellitus.
Methods We analysed data from an observational cohort study, the Fremantle Diabetes Study (FDS), specifically, (1) a cross-sectional sample comprising 1,237 FDS participants with type 2 diabetes mellitus, and (2) a longitudinal subgroup of 531 individuals who had attended six consecutive annual assessments. Neuropathy was identified using the clinical portion of the Michigan Neuropathy Screening Instrument.
Results At entry, the cross-sectional sample had a mean ± SD age of 63.8 ± 11.3 years, 48.7% were men, median (interquartile range) diabetes duration was 4.0 (1.0–9.0) years, and 30.9% had peripheral neuropathy. Fibrates and statins were used by 3.5 and 6.8%, respectively. Multiple logistic regression analysis showed that older age, longer diabetes duration, central adiposity, increased height, higher fasting serum glucose, albuminuria and aboriginality were significant independent positive predictors of prevalent neuropathy, while systolic blood pressure and fibrate use (odds ratio 0.30, 95% CI 0.10–0.86; p = 0.025) were negatively associated. In the longitudinal subgroup, fibrate and statin use increased to 10.4 and 36.5%, respectively, over 5 years. In time-dependent Cox proportional hazards modelling, fibrate use [hazard ratio (HR) 0.52, 95% CI 0.27–0.98] and statin use (HR 0.65, 95% CI 0.46–0.93) were significant determinants of incident neuropathy (p ≤ 0.042).
Conclusions/interpretation These preliminary observational data suggest that therapy with a statin or a fibrate may protect against the development of diabetic peripheral sensory neuropathy, but there is a need for additional confirmatory evidence, preferably from randomised clinical trials.
Cholesterol drugs help diabetic neuropathy
Linear Mode
